Le Lézard
Classified in: Health
Subject: PER

Bayer U.S. Appoints Scott Partridge General Counsel


WHIPPANY, N.J., Oct. 16, 2018 /PRNewswire/ -- Scott Partridge, former vice president of global strategy for Monsanto, now part of Bayer, has been named the company's U.S. General Counsel.

Scott Partridge, Bayer U.S. General Counsel

Partridge, who succeeds former General Counsel Jan Heinemann, began his new role with Bayer on October 1. He reports to Philip Blake, president of Bayer U.S.

"Scott Partridge has been a champion for innovation at Monsanto, and he played an invaluable role in helping us to bring our two great companies together," Blake said. "At this crucial and dynamic time for Bayer, there is no leader more suited and prepared to take on this critical role in the United States."

Partridge received his J.D. and LL.M. from Tulane University School of Law. In 2006, after 27 years in the private practice of law, he joined Monsanto as Chief Deputy General Counsel to lead the international law function, manage litigation, and guide the resolution of significant disputes. In 2008, then-Monsanto Chairman and CEO Hugh Grant appointed Partridge to a newly created business role and tasked him with developing a cross functional team to generate risk mitigation programs and develop integrated competition and communications strategies for the company.

In 2016, the International Institute for Conflict Prevention & Resolution recognized the creation of these unique programs, honoring Partridge and Monsanto with their inaugural Inspiring Innovation Award. At the time of Bayer's acquisition of Monsanto, Partridge was a member of Monsanto's leadership team, overseeing global competition policy, coordinating strategic advocacy on critical issues, and leading the company's dispute resolution activities. Alongside Monsanto's former Chief Technology Officer, Partridge led the team that facilitated the close of the deal that brought the two companies together.

"As we brought these two great companies together, it was remarkable to me the degree of alignment in our strategic vision," Partridge said. "I am proud to bring my experience to the general counsel job in this exciting time."

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.us.

Contact:

Dan Childs
Bayer U.S.
Email: [email protected]
Mobile: (973) 437-0809

Social Media Channels
- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(PRNewsfoto/Bayer)

SOURCE Bayer


These press releases may also interest you

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

23 avr 2024
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

23 avr 2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: